70 Results for "

Protein-protein interaction (PPI)

" in MedChemExpress (MCE) Product Catalog:
Products (70)

70 Results for "Protein-protein interaction (PPI)" in MCE Product Catalog:

12
12 Publications Verification
Cat. No.: HY-135145
CAS No.: 218457-67-1
Purity:  99.89%
Synonyms: CB-103
Target:  

Notch

Research Areas:  

Cancer

Limantrafin (CB-103) is a first-in-class, orally active protein-protein interaction (PPI) inhibitor of the NOTCH transcriptional activation complex. Limantrafin has anti-tumor activity .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-136465
CAS No.: 570390-00-0
Purity:  99.78%
Research Areas:  

Infection

A2ti-1 is a selective and high-affinity annexin A2/S100A10 heterotetramer (A2t) inhibitor with an IC50 of 24 μM . A2ti-1 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. A2ti-1 prevents human papillomavirus type 16 (HPV16) infection .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-115497
CAS No.: 1358488-78-4
Purity:  98.94%
Target:  

E1/E2/E3 Enzyme

Research Areas:  

Infection Inflammation/Immunology

BRD5529 is an effective dose-dependent CARD9-TRIM62 protein–protein interaction (PPI) inhibitor with an IC50 value of 8.6 μM. BRD5529 has potency and complete inhibition of CARD9 ubiquitinylation in vitro, also has favorable solubility. BRD5529 can be used for the research of inflammatory bowel disease (IBD) such as Crohn’s disease (CD) and ulcerative colitis (UC) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-120323
CAS No.: 2101765-81-3
Purity:  98.11%
Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology

DRI-C21045 (compound 10) is a potent and selective inhibitor of the CD40-CD40L costimulatory protein-protein interaction (PPI) with an IC50 of 0.17 μM. DRI-C21045 shows concentration-dependent inhibition of the activation of NF-κB and B cell proliferation all induced by CD40L with IC50s of 17.1 μM and 4.5 μM, respectively .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-111192
CAS No.: 892243-35-5
Purity:  ≥98.0%
Target:  

Ser/Thr Protease

Research Areas:  

Cancer

IPR-803 is a potent inhibitor of the uPAR·uPA protein-protein interaction (PPI). IPR-803 binds directly to uPAR with sub-micromolar affinity. IPR-803 displays anti-tumor activity .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-122862
CAS No.: 2351843-48-4
Purity:  99.57%
Target:  

Ras

Research Areas:  

Cancer

RAS inhibitor Abd-7, a potent RAS-binding compound (Kd=51 nM), is a RAS-effector protein-protein interaction (PPI) inhibitor. RAS inhibitor Abd-7 interacts with RAS inside the cells, prevents RAS-effector interactions and inhibits endogenous RAS-dependent signaling. RAS inhibitor Abd-7 impairs the PPI of various mutant KRAS proteins with PI3K, CRAF and RALGDS as well as NRAS Q61H and HRAS G12V .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-100862
CAS No.: 1622262-55-8
Purity:  98.04%
Target:  

PARP

Research Areas:  

Cancer

BRCA1-IN-2 (compound 15) is a cell-permeable protein-protein interaction (PPI) inhibitor for BRCA1 with an IC50 of 0.31 μM and a Kd of 0.3 μM, which shows antitumor activities via the disruption of BRCA1 (BRCT)2/protein interactions .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-145926
CAS No.: 2654743-22-1
Purity:  99.75%
Target:  

SOS1 Ras

Research Areas:  

Neurological Disease Cancer

MRTX0902 is a potent, selective, brain-penetrant, and orally active SOS1 inhibitor with a Ki of 1.9 nM. MRTX0902 disrupts the SOS1:KRASG12C protein-protein interaction (PPI). MRTX0902 can be used in research on pancreatic ductal adenocarcinoma .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-136466
CAS No.: 482646-13-9
Purity:  99.27%
Research Areas:  

Infection

A2ti-2 is a selective and low-affinity annexin A2/S100A10 heterotetramer (A2t) inhibitor with an IC50 of 230 μM . A2ti-2 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. A2ti-2 prevents human papillomavirus type 16 (HPV16) infection .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-131592
CAS No.: 520-31-0
Purity:  97.73%
Tricetin is a potent competitive inhibitor of the Keap1-Nrf2 Protein Protein Interaction (PPI). Tricetin protects against 6-OHDA-induced neurotoxicity in Parkinson's disease model by activating Nrf2/HO-1 signaling pathway and preventing mitochondria-dependent apoptosis pathway .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-19319
CAS No.: 1628316-74-4
MI-136 is an inhibitor of the menin-MLL protein-protein interaction (PPI), with an IC50 of 31 nM and a Kd of 23.6 nM. MI-136 shows to block AR signaling and has the potential for the study in castration-resistant tumors .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-117233
CAS No.: 1500080-17-0
Purity:  99.63%
Target:  

β-catenin Wnt

Research Areas:  

Metabolic Disease Cancer

UU-T02 is a novel potent, selective small-molecule inhibitor of β-Catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI) with a Ki of 1.36 μM . UU-T02 inhibits canonical Wnt signaling and the growth of colorectal cancer cells .
loading...
    loading...
Cat. No.: HY-153193
CAS No.: 2765539-59-9
Research Areas:  

Metabolic Disease

LSN3160440 is an allosteric modulator of GLP-1R, which acts as a protein–protein interaction (PPI) stabilizer or molecular glue to assist in the adhesion of inactive GLP-1 (9-36) NH2 on GLP-1R .
loading...
    loading...
Cat. No.: HY-132300
CAS No.: 2632259-93-7
Purity:  97.09%
Target:  

β-catenin

Research Areas:  

Cancer

ZW4864 is an orally active and selective β catenin/B-Cell lymphoma 9 protein protein interaction (β catenin/BCL9 PPI) inhibitor. ZW4864 inhibits β catenin/BCL9 PPI with a Ki value of 0.76 μM and an IC50 value of 0.87 μM .
loading...
    loading...
Cat. No.: HY-100341
CAS No.: 312271-03-7
Purity:  ≥98.0%
Research Areas:  

Others

M2I-1 is a Mad2 inhibitor targeting the binding of Mad2 to Cdc20, an essential protein-protein interaction (PPI) within the spindle assembly checkpoint (SAC) .
loading...
    loading...
Cat. No.: HY-147517
CAS No.: 2769963-24-6
Purity:  98.52%
Target:  

Keap1-Nrf2

Keap1-Nrf2-IN-9 (Compound 11) is a potent Keap1-Nrf2 PPI (Keap1-Nrf2 protein-protein interaction) inhibitor with an IC50 of 0.575 μM. Keap1-Nrf2-IN-9 increases the expression of Nrf2 target genes including heme oxygenase 1 (Hmox1), glutathione S-transferase P (GstP), and glutamate-cysteine ligase catalytic (Gclc) and modulatory (Gclm) subunits. Keap1-Nrf2-IN-9 shows no cytotoxic activity in ARPE19 cells .
loading...
    loading...
Cat. No.: HY-147089
CAS No.: 560995-89-3
Purity:  98.55%
PRRSV/CD163-IN-1 is a PRRSV/CD163 inhibitor. PRRSV/CD163-IN-1 can inhibit the interaction between the PRRSV glycoprotein (GP2a or GP4) and the CD163-SRCR5 domain. PRRSV/CD163-IN-1 can be used for the research of porcine reproductive and respiratory syndrome (PRRS) .
loading...
    loading...
Cat. No.: HY-151576
CAS No.: 3031536-71-4
Purity:  98.70%
Research Areas:  

Cancer

PRMT5:MEP50 PPI is a novel PRMT5:MEP50 protein-protein interaction (PRMT5:MEP50 PPI) inhibitor, shows anti-tumor activity and anti-proliferative activity of lung and prostate cancer cells .
loading...
    loading...
Cat. No.: HY-150785
CAS No.: 2166023-31-8
Purity:  99.43%
Target:  

Apoptosis

Research Areas:  

Cancer

TAS1553 is a potent, orally active protein-protein interaction (PPI) inhibitor with an IC50 values of 0.0396 μM. TAS1553 inhibits DNA replication and reduces intracellular dATP pool. TAS1553 induces apoptosis. TAS1553 can be used for cancer research .
loading...
    loading...
Cat. No.: HY-160477
CAS No.: 300713-88-6
Target:  

PIKfyve NF-κB IKK

Research Areas:  

Inflammation/Immunology

DC-SX029 is a potent SNX10 protein-protein interaction (PPI) inhibitor with oral activity with an estimated KD constant of ~0.935 μM by surface plasmon resonance (SPR). DC-SX029 blocks the SNX10-PIKfyve interaction, thereby decreased the TBK1/c-Rel signaling activation. DC-SX029 does not affect the protein level of SNX10. DC-SX029 has the potential for inflammatory bowel disease (IBD) research .
loading...
    loading...